midazolam has been researched along with MODS in 11 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To prospectively study the relationship between inflammation, organ failure, and midazolam clearance as a validated marker of CYP3A-mediated drug metabolism in critically ill children." | 9.22 | Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jerchel, IS; Knibbe, CA; Koch, BC; Mooij, MG; Tibboel, D; van Schaik, RH; Verlaat, CW; Vet, NJ, 2016) |
| "To determine the effect of inflammation and disease severity on midazolam pharmacokinetics (as surrogate marker of cytochrome 3A activity) and pharmacodynamics in critically ill children." | 7.78 | The effect of critical illness and inflammation on midazolam therapy in children. ( de Hoog, M; de Wildt, SN; Tibboel, D; Vet, NJ, 2012) |
| " However, midazolam given in the designated dosage did not offer any modulatory effects on hemodynamic responses, multiple organic dysfunction and survival rate in rats with endotoxemia." | 7.75 | Effects of midazolam on organ dysfunction in rats with endotoxemia induced by lipopolysaccharide. ( Ho, ST; Liaw, WJ; Tsao, CM; Wu, CC, 2009) |
| "Midazolam and metabolites were dosed in plasma and ultratiltration liquid by chromatography." | 6.70 | [Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ( Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Lehot, JJ, 2002) |
| "To prospectively study the relationship between inflammation, organ failure, and midazolam clearance as a validated marker of CYP3A-mediated drug metabolism in critically ill children." | 5.22 | Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jerchel, IS; Knibbe, CA; Koch, BC; Mooij, MG; Tibboel, D; van Schaik, RH; Verlaat, CW; Vet, NJ, 2016) |
| "To assess the effect of continuous hemodiafiltration (CHDF) on ketamine and midazolam kinetics in multiple organ dysfunction syndrome (MODS)." | 5.09 | Ketamine and midazolam kinetics during continuous hemodiafiltration in patients with multiple organ dysfunction syndrome. ( Ishihara, H; Matsuki, A; Okawa, H; Sakai, I; Tsubo, T, 2001) |
| "The recently published pharmacokinetic model for midazolam, quantifying the influence of maturation, inflammation and organ failure in children, yields unbiased clearance predictions and can therefore be used for dosing instructions in term neonates, children and adults with varying levels of critical illness, including healthy adults, but not for extrapolation to preterm neonates." | 3.88 | Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jacqz-Aigrain, E; Knibbe, CAJ; Krekels, EHJ; Swart, EL; Tibboel, D; Valkenburg, AJ; van den Anker, JN; van Gerven, JMA; Vet, NJ, 2018) |
| "To determine the effect of inflammation and disease severity on midazolam pharmacokinetics (as surrogate marker of cytochrome 3A activity) and pharmacodynamics in critically ill children." | 3.78 | The effect of critical illness and inflammation on midazolam therapy in children. ( de Hoog, M; de Wildt, SN; Tibboel, D; Vet, NJ, 2012) |
| " However, midazolam given in the designated dosage did not offer any modulatory effects on hemodynamic responses, multiple organic dysfunction and survival rate in rats with endotoxemia." | 3.75 | Effects of midazolam on organ dysfunction in rats with endotoxemia induced by lipopolysaccharide. ( Ho, ST; Liaw, WJ; Tsao, CM; Wu, CC, 2009) |
| "Midazolam and metabolites were dosed in plasma and ultratiltration liquid by chromatography." | 2.70 | [Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ( Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Lehot, JJ, 2002) |
| "Twenty critically ill patients with acute renal failure on CVVH therapy were administered either lorazepam (n = 10) or midazolam (n = 10) by continuous infusion." | 1.33 | Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ( Danhof, M; de Jongh, J; Strack van Schijndel, RJ; Swart, EL; Thijs, LG; Zuideveld, KP, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, C | 1 |
| Kleinig, P | 1 |
| Bakker, M | 1 |
| Tait, P | 1 |
| Wijnsma, KL | 1 |
| Schijvens, AM | 1 |
| Rossen, JWA | 1 |
| Kooistra-Smid, AMDM | 1 |
| Schreuder, MF | 1 |
| van de Kar, NCAJ | 1 |
| Brussee, JM | 2 |
| Vet, NJ | 3 |
| Krekels, EHJ | 1 |
| Valkenburg, AJ | 1 |
| Jacqz-Aigrain, E | 1 |
| van Gerven, JMA | 1 |
| Swart, EL | 2 |
| van den Anker, JN | 1 |
| Tibboel, D | 3 |
| de Hoog, M | 3 |
| de Wildt, SN | 3 |
| Knibbe, CAJ | 1 |
| Mooij, MG | 1 |
| Verlaat, CW | 1 |
| Jerchel, IS | 1 |
| van Schaik, RH | 1 |
| Koch, BC | 1 |
| Knibbe, CA | 1 |
| Tsao, CM | 1 |
| Wu, CC | 1 |
| Liaw, WJ | 1 |
| Ho, ST | 1 |
| Poloyac, SM | 1 |
| Bastien, O | 1 |
| Bolon, M | 1 |
| Flamens, C | 1 |
| Lehot, JJ | 1 |
| Boulieu, R | 1 |
| de Jongh, J | 1 |
| Zuideveld, KP | 1 |
| Danhof, M | 1 |
| Thijs, LG | 1 |
| Strack van Schijndel, RJ | 1 |
| De Deyne, C | 1 |
| Struys, M | 1 |
| Decruyenaere, J | 1 |
| Creupelandt, J | 1 |
| Hoste, E | 1 |
| Colardyn, F | 1 |
| Tsubo, T | 1 |
| Sakai, I | 1 |
| Okawa, H | 1 |
| Ishihara, H | 1 |
| Matsuki, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bispectral Index Monitoring To Guide Sedation In Patients With Non-Neurological Pathology Over 65 Years, Admitted To Intensive Care Unit: Randomized Control Trial[NCT02909010] | 150 participants (Anticipated) | Interventional | 2015-05-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for midazolam and MODS
| Article | Year |
|---|---|
Palliative sedation: A safety net for the relief of refractory and intolerable symptoms at the end of life.
Topics: Aged; Analgesics; Conscious Sedation; Dehydration; Dyspnea; Humans; Hydromorphone; Hypnotics and Sed | 2019 |
3 trials available for midazolam and MODS
| Article | Year |
|---|---|
Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children.
Topics: Adolescent; Anesthetics, Intravenous; Child; Child, Preschool; Critical Illness; Female; Humans; Inf | 2016 |
[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics].
Topics: Adjuvants, Anesthesia; Aged; Biotransformation; Chromatography, Liquid; Female; Half-Life; Hemofiltr | 2002 |
Ketamine and midazolam kinetics during continuous hemodiafiltration in patients with multiple organ dysfunction syndrome.
Topics: Analgesics; Anti-Anxiety Agents; Female; Glasgow Coma Scale; Hemodiafiltration; Humans; Ketamine; Ma | 2001 |
7 other studies available for midazolam and MODS
| Article | Year |
|---|---|
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Biopsy; Blood Culture; Ceftriaxone; Escher | 2017 |
Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.
Topics: Adult; C-Reactive Protein; Child; Critical Illness; Cytochrome P-450 CYP3A; Humans; Hypnotics and Se | 2018 |
Effects of midazolam on organ dysfunction in rats with endotoxemia induced by lipopolysaccharide.
Topics: Adjuvants, Anesthesia; Animals; Endotoxemia; Hemodynamics; Lipopolysaccharides; Male; Midazolam; Mul | 2009 |
The effect of critical illness and inflammation on midazolam therapy in children.
Topics: Adolescent; C-Reactive Protein; Child; Child, Preschool; Cohort Studies; Critical Illness; Cytokines | 2012 |
Altered drug metabolism in critically ill children: a significant source of adverse effects?.
Topics: Critical Illness; Female; Humans; Inflammation; Male; Midazolam; Multiple Organ Failure | 2012 |
Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Adult; Aged; Conscious Sedation; Drug Administration Schedule; Drug Evaluation; | 2005 |
Use of continuous bispectral EEG monitoring to assess depth of sedation in ICU patients.
Topics: Analgesics, Opioid; Conscious Sedation; Critical Illness; Dose-Response Relationship, Drug; Drug Mon | 1998 |